Indeed, a phase II trial of bicalutamide, an androgen antagonist, in patients with metastatic AR+ER− breast cancer, the 6-month clinical benefit rate was 19% for bicalutamide, which established the potential of targeting AR in ER- disease [23]. This evidence concerns the gene AR and breast cancer.